X4制药 XFOR 深 沪
等待开盘 10-14 09:30:00 美东时间
2.60
-0.220
-7.80%
华盛通- 最 高2.83
- 今 开2.81
- 成交量 43.96万股
- 最 低 2.59
- 昨 收 2.82
- 总市值 2.58亿
- 52周最高 4.83
- 市盈率 静 --
- 换手率 0.44%
- 52周最低 2.59
- 委 比 64.46%
- 总股本 9914.67万
- 历史最高 717.90
- 量 比 0.77
- 振 幅 8.51%
- 历史最低 2.59
- 每 手 1
- 风险率 0.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多X4 Pharmaceuticals secures up to $150M debt facility
X4 Pharmaceuticals (XFOR) said it entered into a senior secured term loan facility of up to $150M with K2 HealthVentures, replacing its previous loan agreement and providing the company with additiona...
10-08 19:33
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth
BioCryst Pharmaceuticals announced the formation of a Scientific Advisory Board (SAB) comprising seven experts in rare disease research and drug development. The SAB will provide strategic guidance to enhance the company's R&D strategy, focusing on external innovation and pipeline expansion. The board includes leaders with extensive experience in rare disease drug discovery, translational science, and clinical development. BioCryst aims to levera...
10-05 11:00
X4 Pharmaceuticals shares are trading lower. The company announced the FDA’s agreement to reduce the 4WARD Phase 3 trial sample size. Enrollment is expected to finish by year-end 2026, with topline data in H1 2028.
X4 Pharmaceuticals shares are trading lower. The company announced the FDA’s agreement to reduce the 4WARD Phase 3 trial sample size. Enrollment is expected to finish by year-end 2026, with topline data in H1 2028.
09-08 22:28
X4 Pharmaceuticals gains FDA support for 4WARD trial
X4 Pharmaceuticals ( ($XFOR) ) has issued an update. X4 Pharmaceuticals, a Bost...
09-08 19:48
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
X4 Pharmaceuticals announced FDA agreement to reduce the sample size of its global 4WARD Phase 3 trial for chronic neutropenia from 176 to 126 participants, maintaining statistical power. The company expects trial enrollment completion by year-end 2026 and topline data in H1 2028. Mavorixafor aims to address chronic neutropenia, a rare blood disorder causing recurrent infections, by mobilizing neutrophils via CXCR4 inhibition.
09-08 11:00
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday. Shares of Airsculpt Technologies Inc (NASDAQ:AIRS) fell sharply in pre-market trading following second-quarter results. AirSculpt Technologies posted second-quarter adjusted earnings of 1 cent per share, ...
08-10 20:02
X4 Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
X4 Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
08-08 00:04
X4 Pharmaceuticals Q2 EPS $(0.13) Beats $(0.18) Estimate, Sales $8.806M Beat $2.420M Estimate
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 96.25 percent increase over losses of $(3.47) per share from the same period last year. The company reported quarterly sales of $8.806 mill...
08-07 05:22
X4 Pharmaceuticals 2026年第二季度财报：许可收入推动营收增至880.6万美元
X4 Pharmaceuticals 2026年第二季度营收880.6万美元，每股亏损0.13美元，净亏损收窄至1615.7万美元。许可收入增长和费用下降推动改善，4WARD三期试验执行仍是后续重点。
08-06 21:06
美股大行评级 | 潜在涨幅98.68%！DA Davidson上调Almonty Industries目标价至33美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持Almonty Industries"买入"评级，目标价从25美元升至33美元；Stifel：维持Nurix Therapeutics"买入"评级，目标价从34美元升至40美元
07-13 10:13
